AAP
DRUG

Arax Advisory Partners’s Bright Minds Biosciences DRUG Stock Holding History

Arax Advisory Partners’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24
Closed -$1.46K – 4200
2025
Q3 		$1.46K Buy
+24
New +$932 ﹤0.01% 3175

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Arax Advisory Partners's DRUG Position: Q4 2025 in Review

Arax Advisory Partners sold out of Bright Minds Biosciences (DRUG) in Q4 2025, closing a stake of 24 shares — an estimated $1.46K sold.

Arax Advisory Partners first reported a position in DRUG in Q3 2025 and held it in 1 quarter. The position peaked at $1.46K in Q3 2025. 74 funds tracked by Wall St. Rank hold DRUG as of Q4 2025.

  • Arax Advisory Partners reported no remaining Bright Minds Biosciences position as of Q4 2025 after selling out during the quarter.
  • Arax Advisory Partners sold 24 Bright Minds Biosciences shares in Q4 2025, an estimated $1.46K.
  • Arax Advisory Partners first reported a position in Bright Minds Biosciences in Q3 2025 and held it in 1 quarter.
  • Arax Advisory Partners's Bright Minds Biosciences position peaked at $1.46K in Q3 2025.
  • 74 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q4 2025.

Based on Arax Advisory Partners's 13F filing for Q4 2025, filed 13 Feb 2026.